PDF《。(hëzâ†Cg⏿4Տy》

24 ??7K?§¨FL$2 3, ?,úCgi

4 D

24 ??7K?¨FL$2 3( P < 0. 05) , ?? 1. ?7Z?(H?8>??°±?? p - MEK ?)?_`H・è??, ?4(wü?l? 5°±?;

?8i?CgD,úCg VSMCs ) p - MEK H???°D:???5?8>??°±, VSMCs ) p - MEK ・è?)c?5°±???:

24 ?? SHR (?8i?CgH÷8 VSMCs ? p - MEK ・è??;

24 ?? WKY (・è?°? ?:??8, ì?"x VSMCs ??・è??;

24 ? ? SHR (H??,úCg VSMCs )?? p - MEK ・ è ? ?;

WKY (  ì ? " x , ú C g VSMCs ??・è??, ?÷ 3( ! 2) . \

1 ^fhc?_`?Ud_`> p - MEK A? VSMCs ?[x±s, "/ 20HPF] 7x ??/? 4(%) 16(%) 24(%) SHR8i?Cg 2.20 ±3.03(0.91) 21.00 ±14.4(5.10) 24.00 ±17.45a (11.82) WKY8i?Cg 5.50 ±5.44(2.97) 4.75 ±5.85(2.18) 15.80 ±25.16(7.59) SHR,úCg 3.40 ±4.09b (5.01) 3.00 ±2.23(5.02) 8.40 ±10.59c (13.55) WKY,úCg 0(0) 1.75 ±2.36(3.17) 4.00 ±3.81(6.97) ( )nr・è°±}%;

a r;

>?? WKY ??,P = 0. 042;

b r;

>?? WKY ??,P = 0000;

cr;

>?? WKY??,P=0.008

3 ?8 >?y3????6\¤?H??, VR G3 >?yH?W?=,/3?.?、?=H]@4 ? [ 1].?é3@?y・rA?H7D?G, ?8C g VR ????>?yH??D?éH{U.` Z?J??? SHR (;

>?? WKY (\?, ?8CgL???H VR ?I$$? [ 2], ?8i? CgD,úCg VSMCs H?Và¨????, SHR (8i?Cg\@n?f???-v?? 8, WKY (?=Y??.9?U3?5y?è ・

7 7

2 1 ・

34 ? >?yz, °8Cg VSMCs ?bc.??Pà ?I?-?????,k??y?GAN>,? VSMCs ?éD°8Cg>??.=HBRè?? Y??. >?y?Il VSMCs ??CH、 ?kH? = [

3 - 4];

VSMCs {U?IH$?@?y?aá?è ~?? [

5 - 7], ò>?y?Il VSMCs 9??= H~???Y?d. MAPK ?`bE?U#;

~>?y VSMCs {U?IH$?.MAPK ?K3eHC?°±n _`?iHG7?=??H?p?/ Ap???, U?@??Q?、 °±Q?、 e?$???W?W è???h?e, ??#;

°±H?é、 8=、 r =、 ???H~ [ 8].°±p~?)??(extra celluar - regulated protein kinases, ERK)

3 MAPK ? `?kP?H???8, :3????é?`rk ??H°±p??.i>?y?Il, ??Cg VSMCs )?h_ ERK -

2 H?? [ 9]. ERK

3 MEK HfGl?ú?, MEK ??=? ? ERK ?, l?H°±???、 ±R、 ±?nH\ T??^ S6 ?)??H?)??ú?V?]? ?, ?????_g?e??J]V?)???r ?Q?H??=, ??~ c - Fos、 c - Myc、 c - Jun、 Egr1 ?4QHr??? [ 10].`Z?@?8i ?CgD,úCg VSMCs HJ???, >PxC g\?, SHR ( p - MEK ・è°±?>5>?? WKY (;

faZ?(???>, SHR ( p - MEK ・è°±}?>Hù°>5>?? WKY ( , 9;

?y?>H??G?.]Vü???] W, SHR 7?é8i?Cg ERK -

2 ・è??}? ?>5 WKY 7;

SHR 7,úCg、8i?Cg VSMCs ) ERK -

2 H

5 WKY

7 [ 11].g?i>?y?Il, np??Q??? ?8Cg VSMCs n MEK ERK - 2, ~l?r?Q?H{U. ??? A2( cytosolic phospholipase A2, cPLA2)

3 ERK ?`bEl?H?`8?, ?bc Ras - Raf - MEK1 /

2 - ERK1 /

2 - cPLA2 c?V??=? =, ?=?H p - cPLA2 #;

~°±H?éD8 = [ 12].`Z?ü?????,SHR (Cg VSMCs ) p - MEK H・è??}>5>?? WKY (;

p - cPLA2 ・è??}?5>?? WKY ( , g? MEK H??D p - cPLA2 H?è???U ??? SHR (Cg VR H?? [ 2, 13].Q.? ?, >?y?Il, np??Q??Ubc\>H ?`??, ???????8Cg VSMCs n, ?? ???sPà?I? k??y? GAN>.`Z??J?|, p - MEK _`??5 ?8>D : ? >

5 ?

8 C g VSMCs, òó?? p - MEK H9????I?U;

>?y?Il?8>??°±H8c{U$?¨ á, Q.g?, p - MEK ????H?~?U3? ?>?y??D??H??Q??G, ??b?? ??è@5>?y?H?T¨??23. XY-B: [ 1] ?・, '8A. >?ygBCH°±??;

??[J] . ??>?$??, 2002, 23( 6) :

356 - 359. [ 2] [\\, F?t, ??, ?. y?è>?y(Cg? >?@H?I$??[J] . ?h"$, 2012, 41( 27) :

2801 - 2803. [ 3] Lenhard SC, Nerurkar SS, Scjaeffer TR, et al. P38 MAPK inhibitors ameliorate target organ damage in hyperter sion: Part 2. Improved renal function as assessed by dy namic contrast - enhanced magnetic resonance [J] . J Pharmacos Exp Therap, 2003, 307:

939 - 946. [ 4] Son YH, Jeong YT, Lee KA, et al. Roles of MAPK and NF - kappaβ in interleukin -

6 induction by lipopolysac charide in wascular smooth nuscle cells[ J] . J Cardiovasc Pharmacol, 2008, 37( 1) :

71 - 77. [ 5] López - Andrés N,Rousseau A,Akhtar R,et al. Car diotrophin

1 is involved in cardiac, vascular, and renal fi brosis and dysfunction. [ J] . Hypertension, 2012, 60( 2) :